Free Trial
NASDAQ:ALPX

Alopexx (ALPX) Stock Price, News & Analysis

→ Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad)
Free ALPX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Alopexx

Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.

ALPX Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ALPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alopexx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPX
CUSIP
N/A
CIK
1880995
Web
www.alopexx.com
Phone
617-780-1598
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Daniel R. Vlock M.D. (Age 70)
    Co-Founder, Pres, CEO & Director
  • Dr. Gerald B. Pier Ph.D. (Age 70)
    Co-Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
  • Mr. Thomas T. Thomas II (Age 64)
    C.F.A., CFA, Chief Financial Officer
  • Dr. William W. Chin M.D. (Age 74)
    Sr. Strategic Advisor & Director
  • Dr. Christine de los Reyes M.B.A. (Age 68)
    Pharm.D., PharmD, Chief Bus. Officer & Chief Commercialization Officer

Key Competitors

View All Competitors

ALPX Stock Analysis - Frequently Asked Questions

When did Alopexx IPO?

Alopexx (ALPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 15th 2023. The company issued 3,000,000 shares at a price of $5.00 per share.

This page (NASDAQ:ALPX) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Wall Street Legend Issues New NVDA Warning
Chaikin Analytics
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency